Transcept Pharmaceuticals Announces FDA Approval of IntermezzoÂ® (zolpidem tartrate sublingual tablet) C-IV For Use as Needed for the Treatment of Insomnia When a Middle-of-the-Night Awakening is Followed by Difficulty Retur